Teasing out valuable data from a sea of text is no mean feat, as Felix Grant discovers
Siân Harris reports on the important role of computing in drug discovery
Beth Harlen presents two case studies exploring how modelling and simulation are changing the face of medical research
Chemistry software will be split between expert tools for computational chemists and 3D desktop modelling tools to support the work of medicinal chemists, says Dr Martin Slater, director of consulting at Cresset
Is HPC becoming an integral part of drug discovery? Industry experts explore the trends
In the battle for processor dominance, who will win out? John Barr weighs up the contenders
The unique requirements of contract research organisations (CROs) demand the deployment of sophisticated informatics systems, as Beth Harlen discovers
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
